SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. This combination will be evaluated under an amendment to the Company’s ongoing Phase 1/2a study of [212Pb]PSV359 in patients with certain types of non-small cell lung cancer and colorectal cancer that express fibroblast activation protein alpha (FAP-α) (clinicaltrials.gov identifier NCT06710756). The study has completed enrollment in the first three monotherapy dose cohorts.

Perspective is sponsoring the study, and Merck is providing pembrolizumab at no cost.

“FAP-α is associated with the majority of solid tumors and with a tumor microenvironment historically characterized by poor drug penetration and immune suppression or exclusion,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “By combining targeted radiopharmaceutical treatment with a well-established immune checkpoint inhibitor, we aim to evaluate whether this approach can reshape the tumor environment and potentially improve treatment outcomes for patients with advanced FAP-α-positive solid tumors.”

About FAP-α

FAP-α is a protein abundantly expressed on the surface of cancer-associated fibroblasts (CAFs) in the stroma, a part of the tumor microenvironment (TME) in the majority of epithelial cancers. In addition to expression on CAFs, FAP-α is expressed on certain cancer cells themselves, including sarcomas and mesotheliomas.1,2,3,4 Higher FAP-α expression has been found to be associated with poor prognosis in a number of solid tumors such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, stomach cancer, mesothelioma, head and neck cancer, esophageal cancer, and ovarian cancer.5,6,7,8,9,10 Expression of FAP-α in healthy tissues is usually low.3,4

About PSV359

PSV359 was designed to target and deliver 212Pb to tumor sites expressing FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with 203Pb or 68Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy as well as human imaging results suggest Perspective’s proprietary targeting ligand has improved levels of target engagement and uptake in tumors, as well as reduced retention in healthy tissues, which may result in a desirable therapeutic index.

Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [212Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [203Pb]PSV359. The primary objective of the dose finding phase of the study is to assess the safety and tolerability of various doses of [212Pb]PSV359 in order to determine the recommended Phase 2 dose to be used in the expansion phase of the study, where anti-tumor activities may be an additional primary outcome measure.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com


1 Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239. doi:10.1073/pnas.87.18.7235
2 Dziadek S, Kraxner A, Cheng WY, et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front Immunol. 2024;15:1352615. Published 2024 Mar 15. doi:10.3389/fimmu.2024.1352615
3 Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi:10.2967/jnumed.119.227967
4 Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3
5 Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396-412.e5. doi:10.1016/j.ccell.2023.12.021
6 Coto-Llerena M, Ercan C, Kancherla V, et al. High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Front Oncol. 2020;10:979. Published 2020 Jul 8. doi:10.3389/fonc.2020.00979
7 Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736-1741. doi:10.1158/1078-0432.CCR-06-1746
8 Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Published 2021 Jul 5. doi:10.1038/s41392-021-00659-4
9 Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154-158. doi:10.1097/MPA.0b013e31816618ce
10 Ma C, Xi S, Sun, H, et al. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15(14):7056-7083. doi: 10.18632/aging.204892

TR-1: Standard form for notification of major holdings

01.  Issuer Details

ISIN            

GB00BLDRH360

Issuer Name    

OSB GROUP PLC

UK or Non-UK Issuer   

UK

02. Reason for Notification

      An acquisition or disposal of voting rights

03. Details of person subject to the notification obligation

Name

Lorentzweiler Adjacent Partners S.C.Sp

City of registered office (if applicable)

Howald

Country of registered office (if applicable)

Luxembourg

04. Details of the sharholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

05. Date on which the threshold was crossed or reached

      09-Sep-2026

06. Date on which Issuer notified

     11-Sep-2026

07. Total positions of person(s) subject to the notification obligation

  % of voting rights attached % of voting rights through financial Total of both in % (8.A + 8.B) Total number of voting rights held in issuer

  to shares (total of 8.A) instruments (total of 8.B 1 + 8.B 2)    
Resulting situation on the date on which threshold was crossed or reached

4.019900

0.000000

4.019900

13637487

Position of previous notification (if applicable)

3.096900

0.000000

3.096900

 

08. Notified details of the resulting situation on the date on which the threshold was crossed or reached

08A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
GB00BLDRH360 13637487 0 4.019900 0.000000
Sub Total 8.A 13637487 4.019900%

08B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights
Sub Total 8.B1      

08B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
Sub Total 8.B2      

09. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the % of voting rights through financial instruments if it equals or is Total of both if it equals or is higher than the notifiable threshold

    notifiable threshold higher than the
notifiable threshold
 
Alan Waxman   3.096900   3.096900%

Alan Waxman

Sixth Street Partners Management Company, L.P.

3.096900

 

    3.096900%

Alan Waxman TAO Finance 3, LLC 1.858100   1.858100%
Alan Waxman Beacon Finance 3, LLC 0.619400   0.619400%

Alan Waxman

Sixth Street Madrone Strategic Holdings I, L.P

0.619400

 

    0.619400%

Alan Waxman

Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)

3.096900

 

    3.096900%

Alan Waxman   4.019900   4.019900%

Alan Waxman

Sixth Street Partners Management Company, L.P.

4.019900

 

    4.019900%

Alan Waxman TAO Finance 3, LLC 2.411900   2.411900%
Alan Waxman Beacon Finance 3, LLC 0.804000   0.804000%

Alan Waxman

Sixth Street Madrone Strategic Holdings I, L.P

0.804000

 

    0.804000%

Alan Waxman

Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)

4.019900

 

    4.019900%

  10. In case of proxy voting        

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11.    Additional Information        

        Correcting notification – UK Issuer

12.    Date of Completion        

               11-Sep-2026

13.    Place Of Completion        

        Luxembourg

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to announce preliminary results for Q4 20261.

  • Record Fourth Quarter Results Lead to Achieving Top End of Fiscal 2026 Production Guidance: In Q4 2026, the Company delivered record quarterly gold production of 8,173 ounces, up 28% from 6,404 ounces in Q4 2025. On a full year basis, the Company delivered record annual gold production of 29,650 ounces, an increase of 57% from 18,935 ounces in 2025, and achieved the top end of its full-year production guidance range of 25,000 to 30,000 ounces.
  • Record Gold Price Realization: During Q4 2026, the Company benefited from a robust average market price for gold of approximately $4,233 per ounce (London PM fix), a 26% increase over the prior year comparative period (Q4 2025: $3,369 per ounce). Combined with higher year over year production, revenue is expected to be significantly higher in Q4 2026 than in the prior year comparative period. On a full year basis, the Company benefited from a record annual average market price for gold of approximately $4,386 per ounce (London PM fix), a 46% increase over the prior year comparative period (2025: $2,999 per ounce). On a full year basis, revenue is expected to be significantly higher in 2026 than in 2025.
  • Process Plant Upgrades Lead to Improved Throughput, Recovery and Gold Production: During Q4 2026 the Company continued to make progress on upgrades to the existing 2,000 tpd processing plant. Notable upgrades to the existing processing plant include a pre-leach thickener, upgraded agitators & interstage screens, Aachen reactor, oxygen plant, Adsorption, Desorption and Recovery (“ADR”) plant, new gold room, apron feeder, belt magnet, and new tertiary crusher. The plant upgrades are in various stages of completion and have already begun to boost plant reliability and performance as evidenced by an increase in plant throughput, gold recovery and gold production in Q4 2026 versus the prior year comparative period.
  • Advancing Process Plant Expansion to Significantly Increase Future Production Capacity: The Company continues to advance its processing plant expansion, a key catalyst for future growth. As previously reported, recent metallurgical test work has led the Company to specify a Semi Autogenous Grind (“SAG”) / Ball mill combination of 3,500 tpd as part of its next processing plant expansion based on optimal grind size for achievable mine feed from the mine plan. Final contract execution for the new SAG / Ball mill was completed in early Q4 2026, initial downpayments have been made, and estimated completion is expected over the next 12 – 18 months. The existing, upgraded 2,000 tpd processing plant will be available to continue operating in conjunction with the new 3,500 tpd SAG / Ball mill processing plant, providing a significant upgrade in processing capacity versus the 3,000 tpd assumed in the PEA. The increase in throughput from the expanded processing plant is expected to produce average annual gold production in excess of the 62,000 ounces of gold originally anticipated in the PEA.
  • Exploration to Ramp-Up Significantly: During fiscal 2026, Buckreef Gold drilled approximately 175 drill holes for a total of 14,500 meters across resource definition, geotechnical, sterilization and greenfield exploration. This was predominantly completed in the second half of fiscal 2026 utilizing one Company owned reverse circulation (“RC”) drill rig and one contractor diamond drill (“DD”) rig. The RC drill rig was commissioned in March 2026 and the DD rig in April 2026. Buckreef Gold also utilized the RC drill rig for ongoing grade control drilling for normal course operations. Buckreef Gold has also purchased: (i) an additional DD drill rig which is currently onsite and being commissioned; (ii) a new RC drill rig which is expected to be onsite in the next 2-4 weeks; and (iii) a new RC/DD combination drill rig which is expected to arrive in the next 4-6 months. These purchases in combination with existing drill rigs on site will significantly increase Buckreef Gold’s drilling capacity and will be utilized for grade control, resource definition, geotechnical, sterilization and greenfield exploration drilling. Given the significant increase in drilling capacity, there will be a significant increase in greenfield exploration, including: (i) the anomalies from the comprehensive geophysics study which identified ten promising targets; and (ii) Stamford Bridge and the Anfield Zone.

Stephen Mullowney, TRX Gold CEO commented: “We are very pleased to have delivered record quarterly and annual gold production in fiscal 2026, achieving the top end of our production guidance while continuing to improve the performance and reliability of our processing plant. The combination of higher production, a robust gold price environment and a strong balance sheet positions us well as we continue to build momentum across the business. Our accelerated plant expansion is laying the foundation for the next stage of growth at Buckreef Gold. The addition of a 3,500 tpd SAG/Ball mill circuit, together with significant upgrades to our existing 2,000 tpd plant, will provide combined processing capacity well beyond the 3,000 tpd capacity contemplated in our PEA last year, unlocking significant value. The improvements we have already made to the existing plant are contributing to higher throughput, recovery and production, while the new SAG/Ball mill represents a significant step forward in our ability to support significantly higher gold production in the years ahead. With a strong balance sheet and a clear path to increased production, we are well positioned to execute on our growth plans and create long-term value for our shareholders.”

About TRX Gold Corporation

TRX Gold is a high margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open pit operation and 2,000 tonnes per day process plant with upside potential demonstrated in the May 2025 Preliminary Economic Assessment (the “PEA”). The PEA outlines average gold production of 62,000 oz per annum over 17.6 years at 3,000 tonnes per day of throughput capacity, and a US$1.9 –US$2.6 billion pre-tax NPV5% at average life of mine gold prices of US$4,000-US$5,000/oz2. The Buckreef Gold Project hosts a Measured and Indicated Mineral Resource of 10.8 million tonnes (“MT”) at 2.57 grams per tonne (“g/t”) gold containing 893,000 ounces (“oz”) of gold and an Inferred Mineral Resource of 9.1 MT at 2.47 g/t gold for 726,000 oz of gold. The leadership team is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold’s actions are led by the highest environmental, social and corporate governance (“ESG”) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

Qualified Person

Mr. Richard Boffey, BE Mining (Hons) F AusIMM, Chief Operating Officer of TRX Gold Corporation, is the Company’s in-house Qualified Person under National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”) and has reviewed and assumes responsibility for the scientific and technical content in this press release.

For investor or shareholder inquiries, please contact:

Investor Relations
IR@TRXgold.com
+1-437-224-5241
+1 844 GOLD TRX (844-465-3879)
www.TRXgold.com

Forward-Looking and Cautionary Statements

This press release contains certain forward-looking statements as defined in the applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “hopes”, “intends”, “estimated”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements relate to future events or future performance and reflect TRX Gold management’s expectations or beliefs regarding future events and include, but are not limited to, statements with respect to future gold prices, continued operating cash flow, expansion of its process plant, estimation of mineral resources, ability to develop value creating activities, recoveries, subsequent project testing, success, scope and viability of mining operations, the timing and amount of estimated future production, and capital expenditure.

Although TRX Gold believes the expectations expressed in such forward-looking statements and the preliminary data included in this press release are based on reasonable assumptions, such statements are not guarantees of future performance. The actual achievements of TRX Gold or other future events or conditions may differ materially from those reflected in the preliminary data and forward-looking statements due to a variety of risks, uncertainties and other factors. These risks, uncertainties and factors include general business, legal, economic, competitive, political, regulatory and social uncertainties; actual results from operations, exploration activities and economic evaluations; fluctuations in currency exchange rates; changes in costs; future prices of gold and other minerals; mining method, production profile and mine plan; delays in exploration, development and construction activities; changes in government legislation and regulation; the ability to obtain financing on acceptable terms and in a timely manner or at all; contests over title to properties; employee relations and shortages of skilled personnel and contractors; the speculative nature of, and the risks involved in, the exploration, development and mining business. These risks are set forth in reports that TRX Gold files with the SEC and the various Canadian securities authorities. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml and the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at www.sedarplus.ca.

The disclosure contained in this press release of a scientific or technical nature relating to the Company’s Buckreef Project has been summarized or extracted from the technical report prepared in accordance with NI 43-101 – Standards of Disclosure for Mineral Projects on the Buckreef Gold Project (“Buckreef Gold”) titled Preliminary Economic Assessment and Updated Mineral Resource Estimate of the Buckreef Gold Mine Project, Tanzania (“PEA”) with an effective date of April 15, 2025. The PEA was prepared in accordance with NI 43-101 guidelines by P&E Mining Consultants Inc. (“P&E”). Input to this PEA was also provided by D.E.N.M. Engineering Ltd. (“D.E.N.M.”). The information contained herein is subject to all of the assumptions, qualifications and procedures set out in, and is qualified in its entirety by reference to the full text of, the PEA and reference should be made to the full details of the PEA which has been filed with the applicable regulatory authorities and is available on the Company’s profile at www.sedarplus.ca. 

The information contained in this press release is as of the date of the press release and TRX Gold assumes no duty to update such information.


1 TRX Gold will provide additional discussion and analysis regarding its Q4 2026 production, sales and financial results when the Company reports its financial statements and Management’s Discussion and Analysis in November 2026. Financial figures quoted throughout are preliminary in nature, unaudited and subject to change.

2 Base case NPV5% of US$701.0 million pre-tax, or US$442.2 million after tax at consensus forecast case gold prices (US$2,707/oz year 1, US$2,646/oz year 2, US$2,495/oz year 3, US$2,400/oz year 4, US$2,245/oz thereafter).

ABB partners with Ferrari Hypersail

As Electrification Partner, ABB will support the development of Ferrari Hypersail's DC power architecture, building on more than 25 years of ABB leadership in DC technology and more than 700 patents.
As Electrification Partner, ABB will support the development of Ferrari Hypersail’s DC power architecture, building on more than 25 years of ABB leadership in DC technology and more than 700 patents.

Zurich, Switzerland, Sept. 14, 2026 (GLOBE NEWSWIRE) —

  • ABB partners with Ferrari Hypersail, an innovative 100-foot oceanic full-foiling monohull yacht powered by renewable energy systems
  • ABB’s 25+ years of DC technology leadership supports development of advanced 800 VDC power systems
  • ABB expertise will help maximize performance and resilience of onboard renewables in extreme ocean conditions

ABB today announces a technology partnership with Ferrari Hypersail that brings ABB’s electrification expertise to the world’s most ambitious offshore challenge. As Electrification Partner, ABB will support the challenge with expertise across marine power, Direct Current (DC) technology and advanced electrical systems.  

Ferrari Hypersail is a groundbreaking 100-foot oceanic full-foiling monohull yacht powered by renewable energy. The vessel is designed to push the boundaries of sustainable marine performance, bringing together speed, resilience and safety with onboard energy generation and management in one of the most technically demanding environments.  

ABB brings more than 25 years of experience in DC technology to the partnership, backed by a portfolio of more than 700 patents in the field. As Electrification Partner, ABB will support Ferrari Hypersail with expertise across energy management, marine electrical systems, energy storage and intelligent monitoring.  

Ferrari Hypersail provides ABB with a high-performance environment to demonstrate how advanced electrification, DC architectures and intelligent energy management can improve resilience and efficiency under extreme offshore conditions. These demands – balancing renewable generation, storage, monitoring and power distribution in real time – are critical to the development of next-generation industrial microgrids. 

“Ferrari Hypersail gives ABB a unique platform to demonstrate how we are collaborating with partners to push the limits of Direct Current technology,” said Giampiero Frisio, President of ABB’s Electrification business area. “Ferrari Hypersail is designed to operate in conditions that are as demanding as anything our systems face in industry. ABB’s role showcases how electrification and automation technologies help industries outrun and achieve record-breaking performance. The lessons from a challenge like this can help us advance the resilient, efficient power systems our customers need across sectors from marine and renewables to data centers and industrial microgrids.” 

For Enrico Voltolini, Project Leader of Ferrari Hypersail, the partnership delivers the technical foundation required to execute the mission. “Hypersail runs entirely on renewable energy,” Voltolini said. “It has to be self-sufficient for weeks at a time in the most hostile ocean environments on earth. Having ABB’s electrification expertise connected to the project is a valuable operational advantage.” 

Ferrari Hypersail’s DC architecture will function as a high-performance, self-sufficient microgrid with systems operating at 48V and 800 VDC. It will generate, store and manage power for critical navigation, foil controls, safety systems and propulsion while operating in conditions of extreme cold, salt spray, pressure and motion.  

ABB’s team will support Ferrari Hypersail with expertise in DC system integration, real-time monitoring, intelligent power distribution and resilience at sea. Insights from the project will help inform the development of advanced power systems for industries including shipping, data centers and renewable energy infrastructure.  

Further information:  
https://www.abb.com/global/en/company/about/engagements-and-partnerships/ferrari-hypersail 

About ABB 
ABB is a global technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. By connecting its engineering and digitalization expertise, ABB helps industries run at high performance while becoming more efficient, productive and sustainable – what we call ‘Engineered to Outrun’. With over 140 years of history and approximately 110,000 employees worldwide, ABB is advancing electrification solutions across power generation, transmission, distribution, and consumption. ABB shares are listed on the SIX Swiss Exchange (ABBN) and Nasdaq Stockholm (ABB). www.abb.com 

Attachment

CONTACT: Sheela Pawar
ABB Electrification
sheela.pawar@ch.abb.com

   Heineken Holding N.V. reports transactions under its current share buyback programme

Amsterdam 14 September 2026 – Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026.

From 7 September 2026 up to and including 11 September 2026 a total of 169,918 shares were repurchased on exchange at an average price of €67.63.

Up to and including 11 September 2026, a total of 3,577,072 shares were repurchased under the second tranche of the share buyback programme for a total consideration of €234,321,209.

Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programme

Enquiries

Media Heineken Holding N.V.    
Kees Jongsma    
tel. +31 6 54 79 82 53    
E-mail: cjongsma@spj.nl

 

   
     
Media   Investors
Christiaan Prins   Tristan van Strien
Director of Global Communications   Global Director of Investor Relations
Marlie Paauw   Lennart Scholtus / Chris Steyn
Global Media Lead   Investor Relations Manager / Senior Analyst
E-mail: pressoffice@heineken.com   E-mail: investors@heineken.com
Tel: +31-20-5239355   Tel: +31-20-5239590

Regulatory information:
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.

Attachment

Heineken N.V. reports the progress of transactions under its current share buyback programme

Amsterdam, 14 September 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 7 September 2026 up to and including 11 September 2026 a total of 167,564 shares were repurchased on exchange at an average price of € 72.01. During the same period, 168,594 shares were repurchased from Heineken Holding N.V.

Up to and including 11 September 2026, a total of 7,186,496 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 509,660,184 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media   Investors
Christiaan Prins   Tristan van Strien
Director of Global Communication   Global Director of Investor Relations
Marlie Paauw   Lennart Scholtus / Isabelle van Rongen
Global Media Lead   Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com   E-mail: investors@heineken.com
Tel: +31-20-5239355   Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

Equifax Canada data shows average debt per business up 7.3 per cent as financial delinquencies reach a multi-year high; pressure builds among higher-risk businesses

Equifax Canada Market Pulse — Q2 2026 Quarterly Business Credit Trends Release

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Canadian businesses are carrying more debt and showing increasing signs of payment stress with banks and lenders, according to new Equifax Canada Q2 2026 Commercial Credit Trends data. In addition recent changes to trade tariffs are creating additional uncertainty for organizations managing elevated debt and cash flow challenges.

Average commercial debt per business rose 7.3 per cent year-over-year to $30,581 in the second quarter, while the 60+ day delinquency rate on financial credit products reached its highest level since 2019 at 4.0 per cent, up 19.7 per cent year-over-year. “The data continues to show an important divide in how Canadian businesses are managing their financial obligations,” said Jeff Brown, Head of Commercial Solutions at Equifax Canada. “Businesses appear to be doing a better job of staying current with suppliers they depend on to keep operating, all the while payment pressure with banks and lenders continues to build. This suggests many businesses are still making difficult choices about where their cash goes.”

Trade tariffs bring uncertainty for key industries
Recent changes to trade tariffs are affecting selected Canadian exports and creating additional pressure for businesses and sectors already managing elevated debt and cash-flow challenges. Business restructuring proposals surged 30.32 per cent year-over-year. At the same time, late payments to suppliers continued to decrease. The 60+ day delinquency rate for industrial trade credit fell 24.4 per cent year-over-year to 4.26 per cent. “This is a period of significant economic and market uncertainty. Equifax Canada is committed to helping lenders make smart lending decisions so that businesses will have the access to capital they need to keep our economy strong,” noted Brown.

Debt growth increasingly concentrated among higher-risk businesses
The increase in business debt is not being felt evenly across the market. High-risk businesses (which are those with the Equifax Business Failure Risk Score between 1026 and 1060) carried the largest average debt load, at $125,517 per business, up 48.2 per cent year-over-year. Businesses in the highest-risk tier saw average balances more than double, increasing 103.1 per cent to $42,986.

Debt also grew sharply among Canada’s youngest businesses. Companies 12 months old or younger, who often have higher start-up costs, recorded a 71.7 per cent year-over-year increase in average debt balances, reaching $48,173.

“These are the businesses we need to watch closely,” said Brown. “Rising debt is not necessarily a sign of financial distress on its own, particularly for a young or growing business. The concern is when rapidly increasing balances are combined with greater difficulty staying current on financial obligations.”

Businesses also continued to shift away from revolving credit. Average line-of-credit balances declined 14.6 per cent year-over-year to $17,570, while average commercial credit card balances fell 8.9 per cent to $5,412. In contrast, average installment loan balances increased 6.9 per cent to $131,107 which may suggest that businesses are seeking out other debt consolidation solutions.

The number of businesses with at least one 30+ day delinquency fell 3.6 per cent year-over-year to 271,645. However, the severity of late payments on financial products continued to increase.

The 60+ day delinquency rate on commercial credit cards rose 24 per cent year-over-year to 4.07 per cent.

Credit performance shows a widening divide among provinces
Ontario recorded the highest provincial financial-trade delinquency rate at 4.44 per cent, followed by Alberta at 3.93 per cent and Manitoba at 3.68 per cent.

The opposite trend is occurring with supplier payments. Industrial trade delinquencies declined across every region, including decreases of more than 20 per cent in Ontario, Quebec, Alberta, Saskatchewan and British Columbia.

British Columbia entered the second half of 2026 with the highest average commercial debt per business in Canada, at $79,171, while commercial credit inquiries in the province declined 4 per cent year-over-year. Atlantic Canada recorded the fastest increase in average business debt, up 21.2 per cent.

“Lower supplier delinquencies are encouraging, but they should not necessarily be interpreted as evidence that business conditions are broadly improving,” added Brown. “When businesses are staying current with suppliers while falling further behind with lenders, it can be an indication that they are prioritizing the payments most essential to keeping the business operating.”

Businesses remain cautious about new credit
Commercial credit inquiries increased 2.6 per cent overall in the second quarter to 259,720.
Manufacturing credit inquiries declined 3.5 per cent year-over-year. The sector also experienced a 21.9 per cent year-over-year increase in 60+ day bank-loan delinquencies, which reached 4.5 per cent.

More businesses seek restructuring
Separate federal insolvency statistics also point to changing patterns among businesses seeking restructuring. According to the Office of the Superintendent of Bankruptcy, there were 1,281 business insolvency filings during the second quarter of 2026, essentially unchanged from a year earlier. However, bankruptcies declined 8.1 per cent while restructuring proposals increased 30.3 per cent year-over-year.

“The shift suggests that a growing proportion of insolvent businesses are attempting to restructure their obligations rather than move directly to bankruptcy,” noted Brown.

Transportation and Warehousing recorded a 36 per cent year-over-year increase in insolvencies, while Construction recorded the largest number of insolvency filings nationally, at 214, a 2 per cent increase year-over-year.

Businesses enter a period of continued economic and trade uncertainty
The Q2 results come as Canadian businesses face continued uncertainty around economic growth, interest rates, operating costs and the evolving Canada-U.S. trade environment.

“For businesses, that makes managing cash flow and understanding their credit position increasingly important,” concluded Brown. “The data suggests many Canadian companies are being cautious about borrowing while managing higher debt and rising payment pressure.”

Equifax is committed to partnering with small business lenders to support the growth and long-term health of Canadian small businesses, empowering Canada’s financial ecosystem with data and insights to move the Canadian economy forward.

Province Analysis – 60+ days Delinquency Rates (Account Level)

Province Delinquency Rate:
Financial Trades
(Q2 2026)
Delinquency Rate
Change: Financial Trades
(Q2 2026 vs. Q2 2025)
Delinquency Rate:
Industrial Trades
(Q2 2026)
Delinquency Rate
Change: Industrial Trades
(Q2 2026 vs. Q2 2025)
Ontario 4.44 % 22.17 % 4.28 % -23.72 %
Quebec 3.57 % 11.00 % 3.24 % -23.92 %
Nova Scotia 3.11 % 26.87 % 4.50 % -29.07 %
New Brunswick 3.19 % 18.38 % 3.72 % -23.38 %
PEI 3.15 % 23.36 % 3.10 % -32.02 %
Newfoundland 3.46 % 21.62 % 3.96 % -20.77 %
Eastern Region 3.20 % 22.59 % 4.02 % -26.60 %
Alberta 3.93 % 20.78 % 5.29 % -25.20 %
Manitoba 3.68 % 15.24 % 3.91 % -13.02 %
Saskatchewan 3.34 % 17.05 % 5.20 % -21.83 %
British Columbia 3.44 % 17.59 % 4.99 % -23.93 %
Western Region 3.65 % 18.84 % 5.00 % -23.23 %
Canada 4.00 % 19.71 % 4.26 % -24.36 %

* Based on Equifax data for Q2 2026

About Equifax
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.ca.

Contact:
Andrew Findlater
SELECT Public Relations
afindlater@selectpr.ca
(647) 444-1197

Angie Andich
Equifax Canada Media Relations
MediaRelationsCanada@equifax.com

NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its proprietary PD-L1/4-1BB bispecific antibody, plus chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC), were presented in an oral presentation at the 2026 World Conference on Lung Cancer (WCLC).

The updated data demonstrated robust and durable antitumor activity across both squamous and non-squamous NSCLC, including high response rates in squamous NSCLC regardless of PD-L1 expression and deep, durable responses in PD-L1-positive non-squamous NSCLC. The findings further support the potential of opamtistomig’s differentiated dual-target mechanism to broaden the clinical benefit of immunotherapy in first-line NSCLC.

Highlights

  • Robust efficacy across NSCLC: As of July 1, 2026, 63 treatment-naïve patients had been enrolled, including 31 non-squamous and 32 squamous NSCLC patients. More than 90% had stage IV disease, and a considerable proportion had multiple metastases, including brain and liver metastases. PD-L1 TPS ≥1% was observed in only 35.5% of non-squamous and 43.8% of squamous patients, well below the 60%–70% in the general NSCLC population. Median follow-up was 7.1 months. Among 62 efficacy-evaluable patients, ORR was 71.0%, DCR was 95.2%, and the 6-month PFS rate was 70.6%.
  • Strong and consistent efficacy in squamous NSCLC: ORR was 87.1%, DCR was 96.8%, and the 6-month PFS rate was 86.7%. Comparable benefit was observed regardless of PD-L1 expression, with ORRs of 84.6% in PD-L1-positive and 88.2% in PD-L1-negative patients, and 6-month PFS rates of 84.6% and 87.4%, respectively.
  • Deep and durable responses in non-squamous NSCLC: Among PD-L1-positive patients, ORR was 81.8%, DCR was 100.0%, and the 6-month PFS rate was 90.0%. Notably, substantial responses were also observed in patients with low PD-L1 expression (TPS 1%–49%).
  • Favorable safety: Opamtistomig plus chemotherapy demonstrated a manageable safety profile generally consistent with PD-(L)1 antibody-based chemotherapy combinations, with no new safety signals observed.

These findings support the potential of opamtistomig’s differentiated PD-L1/4-1BB dual-target mechanism to provide broad and durable clinical benefit across PD-L1 expression levels, including patient populations that remain underserved by conventional immunotherapy.

As the first PD-L1/4-1BB bispecific antibody to enter NDA review globally, opamtistomig is being developed as a potential next-generation IO 2.0 backbone therapy. It is currently being evaluated in 14 solid tumor indications, with clinical evidence emerging across seven tumor types, including NSCLC, ESCC, EP-NEC, BTC, and platinum-resistant ovarian cancer. Approximately 800 patients with solid tumors have been treated to date, with a favorable overall safety profile.

Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: “The updated WCLC data are highly encouraging. With longer follow-up, tumor shrinkage continued to deepen and ORR continued to increase, providing further evidence of the durability of opamtistomig’s antitumor activity. Particularly noteworthy is the consistent efficacy observed regardless of PD-L1 expression in squamous NSCLC, together with deep and durable responses in PD-L1-positive non-squamous NSCLC, including patients with low PD-L1 expression.

Despite more than 90% of patients having stage IV disease and many presenting with difficult-to-treat metastatic disease, opamtistomig plus chemotherapy continued to demonstrate encouraging efficacy and PFS outcomes. These findings further support its potential clinical value in first-line NSCLC. We are advancing Phase III development and look forward to bringing this next-generation immunotherapy to more patients.”

About NSCLC
According to data from the International Agency for Research on Cancer (IARC) in 2022, there are approximately 2.48 million new cases of lung cancer and approximately 1.82 million lung cancer-related deaths worldwide each year. According to data published by the National Cancer Center of China, there were approximately 1.18 million new lung cancer cases and approximately 743,000 lung cancer-related deaths in China in 2024. NSCLC accounts for approximately 85% of all lung cancer cases. Due to the aggressive nature of NSCLC and the lack of effective early screening methods, approximately 70% of patients with NSCLC in China are diagnosed at an advanced stage.

Patients with NSCLC harboring actionable genetic alterations (AGAs) such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) may benefit from corresponding targeted therapies, while patients without AGAsstill rely primarily on immunotherapy in combination with chemotherapy. Further prolonging survival and achieving more durable and deeper responses remain key unmet needs in clinical practice. In squamous NSCLC, AGAs are rare, and patients generally cannot benefit from targeted therapies. Commonly used drugs such as pemetrexed and bevacizumab are also unsuitable for squamous NSCLC due to efficacy or safety concerns, resulting in limited treatment options. Although PD-1/PD-L1 inhibitors in combination with chemotherapy have expanded treatment options for patients with squamous NSCLC, prognosis remains poorer than in non-squamous NSCLC due to differences in biology, clinical features and treatment responses, with a median PFS of only 5 to 8 months and a median overall survival (OS) of 17 to 27 months, highlighting a significant unmet medical need for more effective treatment options.

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Currently, opamtistomig is being evaluated in 14 indications, including one pivotal single-arm registrational study, one confirmatory Phase III study, and nine proof-of-concept studies, covering major indications such as NSCLC and multiple cold tumors. To date, opamtistomig has demonstrated robust antitumor activity across seven tumor types—extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC)—highlighting its clinical value and broad therapeutic promise.

Developed using Leads Biolabs’ proprietary X-Body bispecific platform, opamtistomig is designed to simultaneously block PD-1/PD-L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically “cold” tumors and potentially offering durable survival benefits.

Recognizing its clinical potential, opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in November 2024. Additionally, in January 2026, opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission, further underscoring its potential to address unmet medical needs in this patient population. In July 2026, its New Drug Application (NDA) was granted priority review designation by the NMPA, followed by NDA acceptance in August 2026, positioning opamtistomig as a potential world’s first approved 4-1BB-targeting antibody, the first approved agonist antibody, and the first approved treatment for EP-NEC.

About Leads Biolabs
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 15 innovative drug candidates, including five clinical-stage drug candidates and one registration-stage asset.

The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios.

Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit
https://en.leadsbiolabs.com/

CONTACT: Contact:
yizi@leadsbiolabs.com

New ad spot, produced by Colin Jost’s No Notes Productions, airs during NFL Monday Night Football, as part of the company’s Zoom Ahead campaign

SAN JOSE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Zoom (NASDAQ: ZM) today introduced the next chapter of its Zoom Ahead marketing campaign with a new hero tv spot, “Zoom Got It Done.” The commercial highlights how Zoom’s AI-first platform helps finish the work that originates in conversations.

Across both traditional and digital media, the effort focuses on demonstrating Zoom’s product breadth: an ecosystem that goes far beyond video meetings to include AI agents, automated note-taking, contact center solutions, a productivity suite, and more.

The new commercial picks up where last year’s “I Use Zoom!” spot, featuring Bowen Yang, ended.

“The first ad showed that people prefer Zoom. This one shows why: Zoom actually helps users get work done,” said Kimberly Storin, CMO at Zoom. “Only Colin Jost and Kate McKinnon could turn that into a punchline instead of a product demo.”

Reframing Perception Through Comedy: The “Zoom Got It Done” Ad Spot
Kate McKinnon stars in the ad as an over-the-top CEO who orders her staff to find a way to destroy Zoom once and for all. But every scheme instead ends up proving the value of the Zoom platform in helping get things done — even its own destruction.

Produced in partnership with Colin Jost’s No Notes Productions, the ad showcases a variety of Zoom use cases through a zany yet accurate comedic treatment, turning what could have been a feature readout into something clear, digestible, and funny.

“As someone who aspires to be an evil CEO someday, it was wonderful to live out my dream through Kate McKinnon in this Zoom campaign,” said Colin Jost, founder of No Notes Productions.

“Zoom Got It Done” debuts during Week 1 of the NFL regular season on Monday Night Football, then continues across linear and connected TV, out-of-home, digital, and social placements. The wider Zoom Ahead marketing campaign also continues, featuring creator partnerships, new branded content assets, and Zoom’s MLB sponsorship.

Defining Conversation to Completion
The goal of the Zoom Ahead campaign is to inform users of Zoom’s new and extended product capabilities, a concept the company calls “conversation to completion.”

Across tools like Meetings, Chat, Contact Center, and more, Zoom hosts millions of conversations every day. Through Zoom’s advanced AI capabilities, users can now harness the context of these conversations, and use them to move work towards completion. This allows users to automate things like follow-up emails, meeting summaries, and reports, or even bring that context into 3rd party platforms.

For more on Zoom’s AI-first capabilities, www.zoom.com.

About Zoom
Zoom (NASDAQ: ZM) is an AI-first work platform built for human connection, designed to move conversations to completion. From solopreneurs to global enterprises, customers use Zoom to communicate, collaborate, and get work done across meetings, chat, phone, contact center, events, and more, all supported by Zoom AI. Founded in 2011, Zoom is headquartered in San Jose, California. For more information, visit zoom.com.

Press Contact
Rebecca Bernhard
rebecca.bernhard@zoom.com
press@zoom.us

To
Nasdaq Copenhagen A/S
  Executive Management
Bernstorffsgade 40
DK-1577 København V
www.rd.dk

Telephone +45 7012 5300

14 September 2026

Auctions of mortgage covered bonds series 10F and 10G for the refinancing of FlexLån®

Realkredit Danmark will hold auctions on mortgage covered bonds (SDRO) for the refinancing of FlexLån® as of 1 January 2027. The auctions in series 10F and 10G will be held in the period from 16 November to 20 November 2026.

The preliminary amounts and the distribution on specific ISIN’s are expected to change in the weeks to come. As a consequence, the specific auction dates for the individual ISIN’s will not be announced until the final amounts are known.

The preliminary amount of bonds for the refinancing auctions is listed in the appendix.

The preliminary amount of bonds for the refinancing of FlexLån® in series 10F and 10G will be updated weekly on rd.dk/Investor starting from week 41.

The final amount of each ISIN to be auctioned including the specific auction dates for each ISIN will be announced early November.

The Executive Management        

Any additional questions should be addressed to Christian Rosenstand, Head of RD Funding, phone
+45 45 13 20 19.

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.